📉 Khalifa misses 50 Cr mark, facing another flop

Prithviraj Sukumaran’s action thriller, Khalifa, is reportedly heading towards a box-office failure despite a strong start. The film was released in theaters for Onam and currently stands at a worldwide gross of 42.59 crore. After 11 days, the movie earned only 0.93 crore on Day 11, bringing the net total to 19.57 crore. Negative reviews and competition from Bethlehem Kudumba Unit have slowed its momentum significantly. At this rate, Khalifa is expected to miss the 50 crore milestone globally. 😟

🩺 Blood clot risks linked to young stroke cases

Mechanical risk factors for venous thrombosis within 14 days before stroke were linked to cryptogenic ischemic stroke in young adults. The study involved 546 patients aged 18-49 years, including 47.25% women, in a multicenter case-control study. Mechanical VTRFs in the last 14 days were more prevalent in cases (15.4% vs 9.6%) and had an OR of 1.67. This link was stronger in those 18-39 years old and with a patent foramen ovale. Clinicians should assess these factors for young patients lacking conventional stroke risk factors. 🩺

🧠 Evening exercise boosts memory despite less sleep

A trial found that one 30-minute evening exercise session protected long-term memory in young adults facing sleep restriction. Researchers conducted this randomized controlled trial with 88 healthy young adults at Concordia University in Montreal. The study tracked memory performance after sleep restriction versus exercise-plus-restriction during the period of August 26. The results showed that exercise offset memory deficits caused by limited sleep, mediated by slow-wave sleep. This suggests acute exercise could help hippocampal memory in people prone to sleep loss. 🧠

🩺 MASLD now spans three specialties thanks to new drugs

MASLD management has fundamentally shifted as it now crosses primary care, endocrinology, and gastroenterology. Two major FDA approvals, Resmetirom in March 2024 and Semaglutide in August 2025, drove this change. New 2026 guidelines recommend FIB-4 screening for almost all T2D patients every one to two years. Specialists are now reserved for advanced fibrosis or complex cases, not initial screening. The bottleneck remains in second-tier testing capacity for indeterminate results. 🩺

🔬 Tofacitinib solo works just as well as combo therapy

A retrospective study compared treatment persistence for rheumatoid arthritis patients using tofacitinib. Researchers analyzed data from six Dutch cohorts, involving 2684 adults between 2001 and 2022. The findings showed no significant difference in drug survival between tofacitinib monotherapy and combination therapy across ACPA subgroups. However, adalimumab combination therapy showed a lower risk of discontinuation. This suggests solo tofacitinib is a viable option in real-world settings. 🧐

🎬 Hi recovers 28% of budget after slow start

The romance drama 'Hi' has started slow at the box office but is showing growth. Starring Nayanthara and Kavin, the film was released recently in India. Over its opening weekend, it earned a net total of 5.6 crore against a 30 crore budget. The film has recovered 28% of its production cost, driven by positive word-of-mouth. It is expected to slowly become profitable with continued audience support. 🎬

🏥 New guidelines boost sepsis care systems

Hospital-level sepsis interventions across diagnosis and antimicrobial stewardship can significantly improve patient outcomes. This new position paper, from IDSA, suggests focusing beyond initial care for better prevention. It advises using multiplex nucleic acid tests and keeping antibiotic administration times super quick. The recommendations aim to complement existing guidelines by focusing on broader systemic changes. Hospitals are encouraged to adopt expanded performance measures to refine and improve care.

🚀 Ravi Teja's Irumudi Smashes Tollywood's 2nd Sunday Record

The film Irumudi, starring Ravi Teja, is having a massive run at the Indian box office. It achieved Tollywood's biggest second Sunday of 2026 on the second Sunday, overtaking Ram Charan's Peddi. On day 10, the Telugu entertainer earned 15 crore, marking a 21.95% jump from day 9's 12.3 crore. With a budget of 35 crore, it has grossed 129.55 crore net, leading to a 270.14% ROI. The film is currently on track to cross the 200 crore net collections mark. 📈

🧠 ALS blood marker links to new treatment hope

Researchers identified elevated blood levels of N-acyl taurines as a marker for rapidly progressing ALS in Japan. These NATs were found to correlate with shorter survival times in patients. In experiments using patient cells and mouse models, a compound targeting NAT breakdown slowed motor decline and extended survival. This suggests a new drug discovery route starting from patient metabolic changes. Future studies are needed to confirm NATs as a practical biomarker and understand the full mechanism. 🔬

🔬 Tiny device detects cancer and HIV at home

Researchers developed the VPodDuoss, a handheld device capable of detecting pathogens and cancer biomarkers without needing a lab. Han-Keun Lee and his team at the University of Illinois Urbana-Champaign created this by miniaturizing complex fluorescence assay technology. Promising results were published in IEEE Sensors Journal in July 2026, showing comparable accuracy to lab-grade fluorimeters for HIV and lung cancer. The device, which is about the size of AirPods, aims to make point-of-care diagnostics more accessible. The team is now working on improving automation before aiming to bring the technology to the market. 🔬

🚀 Nivin Pauly's film hits super hit status

Nivin Pauly and Mamitha Baiju's 'Bethlehem Kudumba Unit' is showing massive success at the box office. The Malayalam film is performing strongly both domestically and overseas. In 10 days, it earned 82.45 crore net in India and 10 crore overseas, hitting a worldwide gross of 195.79 crore. Based on a 30 crore budget, the film has already secured a 174% return on investment. It is expected to reach the 200% return milestone by Tuesday after the Onam holidays end. 🎬